Every 10-Q that Kodiak Sciences Inc (KOD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow KOD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KOD filings page.
Kodiak Sciences Inc. is a precommercial retina-focused biotechnology company advancing three late-stage programs (Zenkuda/tarcocimab, KSI-501 and KSI-101) and several earlier pipeline assets. Zenkuda has completed four Phase 3 pivotal studies in diabetic retinopathy, retinal vein occlusion and wet AMD, with the DAYBREAK Phase 3 wet AMD trial and KSI-501’s registrational DAYBREAK and ALTO studies fully enrolled or enrolling. KSI-101 is in two Phase 3 MESI trials (PEAK and PINNACLE) with first pivotal data expected in December 2026.
For the quarter ended June 30, 2026, Kodiak reported a net loss of $65.6 million (vs. $54.3 million a year earlier) and a six‑month loss of $123.8 million. Research and development expenses rose to $56.1 million in the quarter, driven by expanded KSI‑501 and KSI‑101 clinical and manufacturing activity. Cash and cash equivalents were $125.9 million with an accumulated deficit of $1.7 billion. Management states there is substantial doubt about the company’s ability to continue as a going concern without additional financing, even though current cash is expected to fund operations into 2027.
Kodak Sciences Inc. (KOD) remains a precommercial retina-focused biotech, reporting a net loss of $58.2 million for the quarter ended March 31, 2026, on operating expenses of $59.8 million. Research and development was $48.5 million, driven by late-stage programs Zenkuda (tarcocimab), KSI-501 and KSI-101, while general and administrative costs fell to $11.2 million as prior lease impairment and higher stock-based compensation rolled off.
Cash and cash equivalents were $169.5 million, with total assets of $306.0 million and a $100.0 million liability related to the sale of future royalties. Operating cash burn was $40.0 million in the quarter. The company has an accumulated deficit of $1.62 billion and discloses that its financial condition raises substantial doubt about its ability to continue as a going concern, even as it plans additional financing to support Phase 3 trials and prospective biologics license applications in diabetic retinopathy, retinal vein occlusion, wet AMD and macular edema secondary to inflammation.
Kodiak Sciences (KOD) reported a wider quarterly loss and flagged going concern risk. For the quarter ended September 30, 2025, net loss was $61.5 million with basic and diluted loss per share of $1.16. Year-to-date net loss reached $173.2 million as research and development spending rose to support multiple late‑stage programs.
Cash and cash equivalents were $72.0 million as of September 30, 2025, down from $168.1 million at year‑end, with $96.6 million used in operating activities over nine months. Management states there is substantial doubt about the company’s ability to continue as a going concern without additional financing. Stockholders’ equity was $23.7 million; a $100.0 million liability related to sale of future royalties remains outstanding.
Pipeline progressed with Phase 3 studies: GLOW2 (DR) and DAYBREAK (wet AMD) have completed enrollment, with topline readouts targeted for 1Q 2026 and 3Q 2026, respectively. KSI‑101 Phase 3 (MESI) trials PEAK and PINNACLE are enrolling, with topline data targeted for 4Q 2026 and 1Q 2027. As of November 6, 2025, common shares outstanding were 53,048,428.
Kodiak Sciences Inc. (KOD) reported continued clinical progress alongside significant cash burn and liquidity concerns. For the six months ended June 30, 2025 the company recorded a net loss of $111.8 million and used $63.8 million of cash in operations. The company reported $104.2 million of cash and cash equivalents as of June 30, 2025 (and $110.349 million including restricted cash), an accumulated deficit of $1,440,512 (amounts presented in thousands) and a $100,000 liability related to the sale of future royalties. Management states there is substantial doubt about the company’s ability to continue as a going concern and plans to seek additional financing.
Operationally, Kodiak is advancing multiple late-stage programs. GLOW2 enrollment is complete (more than 250 patients) with topline data expected 1Q 2026; DAYBREAK (tarcocimab and KSI-501) remains actively enrolling with topline data expected 3Q 2026 and the company intends to seek a single BLA in 2026 following these results. KSI-101 completed Phase 1b APEX with selected doses moving into Phase 3 PEAK and PINNACLE, which are actively enrolling. The company recognized a $1.9 million non-cash lease impairment tied to a sublease and recorded sublease income in 2025. Research and development expense rose materially to $86.4 million for the six months ended June 30, 2025, reflecting expanded pivotal trials and manufacturing work.